Angel Alexis Priego-Ranero

Dr. Angel Alexis Priego-Ranero

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
EMEduardo Martín-Nares
Eduardo Martín-Nares
GHGabriela Hernandez-Molina
Gabriela Hernandez-Molina
APAngel Alexis Priego-Ranero
Angel Alexis Priego-Ranero
ICIsela Chan-Campos
Isela Chan-Campos
GHGladys S. Herrera-Noguera
Gladys S. Herrera-Noguera
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
Diverse immune cell subsets have been described in IgG4-related disease (IgG4-RD). If there is a different immunophenotype according to clinical phenotype and activity status is not known. Levels of IL-4-, IL-13-, IL-5-, and IL-21-producing CD4+ T cells (Th2 subsets), CD4+ cytotoxic T lymphocytes (CD4+CTLs), T helper 9 cells, T follicular helper cells (Tfh; Tfh1/Tfh2/Tfh17/Tf regulatory [Tfr]), Foxp3+ regulatory T cells, Type 1 regulatory T cells (Tr1), T helper 3 regulatory cells (Th3), IL-10-producing regulatory B cells (Bregs), IL-10-expressing regulatory plasmacytoid dendritic (pDC IL-10+) cells, and M1 and M2 monocytes were determined by flow cytometry in 43 IgG4-RD patients and 12 controls. All immune subsets were higher in patients vs. controls. CD4+/IL-4+, CD4+/IL-5+, CD4+CTLs, Tfh2, Tfh17, Tfr, and M1 monocyte cell number was different among IgG4-RD clinical phenotypes. The pancreato-hepato-biliary phenotype was characterized by a higher CD4+CTLs, Tfh17, Tfh2, and Tfr and lower M1 cell number. An increased CD4+CTLs and Th3 cell number distinguished the head and neck-limited phenotype, while the retroperitoneal/aortic and Mikulicz/systemic phenotypes were characterized by increased Th2 subsets. Tfh17, Tr1, Th3, pDC, M1, and M2 monocytes were augmented in active patients. In summary, the clinical heterogeneity of IgG4-RD might be driven by the participation of different immunophenotypes and, consequently, by a different fibroinflammatory process.

16 March 2022 in Clinical and Translational Medicine
Verified
Journal Article
Open access
SMSilvia Méndez‐Flores
Silvia Méndez‐Flores
APAngel Alexis Priego-Ranero
Angel Alexis Priego-Ranero
DADaniel Azamar‐Llamas
Daniel Azamar‐Llamas
HOHéctor Olvera‐Prado
Héctor Olvera‐Prado
KRKenia Ilian Rivas‐Redonda
Kenia Ilian Rivas‐Redonda
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda

Verified
Journal Article
Open access
PDF file
EOElizabeth Olivares-Martínez
Elizabeth Olivares-Martínez
DHDiego Francisco Hernández-Ramírez
Diego Francisco Hernández-Ramírez
CNCarlos Alberto Núñez-Álvarez
Carlos Alberto Núñez-Álvarez
DMDAVID EDUARDO MEZA-SANCHEZ
DAVID EDUARDO MEZA-SANCHEZ
MCMónica Chapa
Mónica Chapa
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
The intramuscular administration of polymerized type I collagen (PTIC) for adult symptomatic COVID-19 outpatients downregulated hyperinflammation and improved symptoms. We inferred that LAIR1 is a potential receptor for PTIC. Thus, a binding assay and surface plasmon resonance binding assay were performed to estimate the affinity of the interaction between LAIR1 and PTIC. M1 macrophages derived from THP-1 cells were cultured with 2–10% PTIC for 24 h. Lysates from PTIC-treated THP-1 cells, macrophage-like cells (MLCs), M1, M1 + IFN-γ, and M1 + LPS were analyzed by Western blot for NF-κB (p65), p38, STAT1, and pSTAT1 (tyrosine701). Serum cytokine levels and monocyte LAIR1 expressions (Mo1 and Mo2) were analyzed by luminometry and flow cytometry in symptomatic COVID-19 outpatients on PTIC treatment. PTIC-bound LAIR1 had a similar affinity to collagen in M1 macrophages. It downregulated pSTAT1 in IFN-γ-induced M1. COVID-19 patients under PTIC treatment showed a significant decrease in Mo1 percentages and cytokines (IP-10/MIF/eotaxin/IL-8/IL-1RA/M-CSF) associated with STAT1 and an increase in the Mo2 subset. The inflammatory mediators and Mo1 downregulation were related to better oxygen saturation and decreased dyspnea, chest pain, cough, and chronic fatigue syndrome in the acute and long-term phase of infection. PTIC is an agonist of LAIR1 and downregulates STAT-1 phosphorylation. PTIC could be relevant for treating STAT1-mediated inflammatory diseases, including COVID-19 and long COVID.

7 March 2022 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
APAngel Alexis Priego-Ranero
Angel Alexis Priego-Ranero
Ghislain OpdenakkerGhislain Opdenakker
Ghislain Opdenakker
NUNorma Uribe‐Uribe
Norma Uribe‐Uribe
DADiana Aguilar‐León
Diana Aguilar‐León
CNCarlos A. Nuñez‐Álvarez
Carlos A. Nuñez‐Álvarez
GTGonzalo Torres-Villalobos
Gonzalo Torres-Villalobos

30 July 2021 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
Gabriela Fonseca-CamarilloGabriela Fonseca-Camarillo
Gabriela Fonseca-Camarillo
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
APAngel Alexis Priego-Ranero
Angel Alexis Priego-Ranero
RZRafael Barreto Zúñiga
Rafael Barreto Zúñiga
BMBraulio Martínez-Benítez
Braulio Martínez-Benítez
Jesus K. Yamamoto-FurushoJesus K. Yamamoto-Furusho
Jesus K. Yamamoto-Furusho

11 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EOElizabeth Olivares-Martínez
Elizabeth Olivares-Martínez
DHDiego Francisco Hernández-Ramírez
Diego Francisco Hernández-Ramírez
CNCarlos Alberto Núñez-Álvarez
Carlos Alberto Núñez-Álvarez
DMDAVID EDUARDO MEZA-SANCHEZ
DAVID EDUARDO MEZA-SANCHEZ
MCMónica Chapa
Mónica Chapa
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
The intramuscular administration of polymerized type I collagen (PTIC) for adult symptomatic COVID-19 outpatient downregulated hyperinflammation and improved symptoms. We inferred that LAIR-1 is a potential receptor for PTIC. Thus, binding assay and surface plasmon resonance binding assay were performed to estimate the affinity of the interaction between LAIR-1 and PTIC. M1-macrophage derived from THP-1 cells were cultured with 2-10% PTIC for 24 h. Lysates from PTIC-treated THP-1 cells, macrophages-like cells (MLCs), M1, M1+IFN-γ, and M1+LPS were analyzed by western blot for NF-κB(p65), p38, STAT-1, and pSTAT-1 (tyrosine701). Serum cytokine levels and monocyte LAIR-1 expression (Mo1 and Mo2) were analyzed by luminometry and flow cytometry in symptomatic COVID-19 outpatients on PTIC treatment. PTIC-bound LAIR-1 with a similar affinity to collagen in M1-macrophages. It downregulated pSTAT-1 in IFN-γ-induced M1. COVID-19 patients under PTIC treatment significantly decreased Mo1 percentage and cytokines (IP-10/MIF/eotaxin/IL-8/IL-1RA/M-CSF) associated with STAT-1 and increased Mo2 subset. The inflammatory mediators and Mo1 downregulation were related to better oxygen saturation and decreased dyspnea, chest pain, cough, and chronic fatigue syndrome in the acute and long-term phase of infection. PTIC is an agonist of LAIR-1 and downregulates STAT-1 phosphorylation. PTIC could be relevant for treating STAT-1-mediated inflammatory diseases, including COVID-19 and long-COVID.